Global Oligonucleotide Synthesis Market To Cross USD 7 Billion By 2032 | Delveinsight

(MENAFN- GlobeNewsWire - Nasdaq) The increasing occurrence of genetic disorders is a major factor fueling the demand for oligonucleotide synthesis, as these molecules are essential for gene therapies and diagnostics aimed at hereditary diseases. The growing application of oligonucleotides in therapeutics, especially antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), has created new opportunities for treating conditions like spinal muscular atrophy and hereditary amyloidosis.

New York, USA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Global Oligonucleotide Synthesis Market to Cross USD 7 Billion by 2032 | DelveInsight

The increasing occurrence of genetic disorders is a major factor fueling the demand for oligonucleotide synthesis, as these molecules are essential for gene therapies and diagnostics aimed at hereditary diseases. The growing application of oligonucleotides in therapeutics, especially antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), has created new opportunities for treating conditions like spinal muscular atrophy and hereditary amyloidosis.

DelveInsight's Oligonucleotide Synthesis Market Insights report provides the current and forecast market analysis, individual leading oligonucleotide synthesis companies' market shares, challenges, oligonucleotide synthesis market drivers, barriers, trends, and key market oligonucleotide synthesis companies in the market.

Key Takeaways from the Oligonucleotide Synthesis Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global oligonucleotide synthesis market during the forecast period.
• In the product type segment of the oligonucleotide synthesis market, the synthesized oligonucleotides category is expected to hold a significant share in the coming years.
• Notable oligonucleotide synthesis companies such as Thermo Fisher Scientific Inc., Agilent Technologies, Merck KGaA, Bio-Synthesis Inc., Ajinomoto Bio-Pharma Services, CordenPharma, Creative Biolabs, Ella Biotech, Eurofins Genomics, Future synthesis, Integrated DNA Technologies, Kaneka Eurogentec, LGC Biosearch Technologies, Microsynth, Nitto Avecia, Ribo Biotechnology, STA Pharmaceutical, Sumitomo Chemical, TriLink Biotechnologies, Sarepta Therapeutics, and several others, are currently operating in the oligonucleotide synthesis market.
• In June 2024, GSK completed the acquisition of Elsie Biotechnologies for USD 50 million to strengthen its oligonucleotide research and development capabilities.
• In April 2024, Asahi Kasei Bioprocess agreed with Axolabs to build a 59,000-square-foot oligonucleotide cGMP manufacturing facility in Germany.

To read more about the latest highlights related to the oligonucleotide synthesis market, get a snapshot of the key highlights entailed in the Global Oligonucleotide Synthesis Market Report

Oligonucleotide Synthesis Overview

Oligonucleotide synthesis is a chemical process used to create short sequences of nucleotides, typically ranging from a few to around 200 bases in length. These synthetic DNA or RNA fragments are widely used in molecular biology, diagnostics, therapeutics, and gene editing applications. The synthesis process primarily relies on phosphoramidite chemistry, where nucleotides are sequentially added to a growing chain in a 3' to 5' direction. Each cycle involves four key steps-deprotection, coupling, capping, and oxidation-ensuring high fidelity and efficiency. Automated synthesizers have revolutionized this process, allowing for rapid, scalable production of oligonucleotides with high purity and precision.

Advancements in oligonucleotide synthesis have enabled the development of various therapeutic modalities, including antisense oligonucleotides, small interfering RNA (siRNA), and aptamers. Chemical modifications, such as phosphorothioate backbones, locked nucleic acids (LNAs), and conjugation with delivery molecules, enhance stability, specificity, and cellular uptake. These innovations have led to FDA-approved oligonucleotide-based drugs for diseases such as spinal muscular atrophy and Duchenne muscular dystrophy. As synthesis technologies continue to evolve, the field is moving towards cost-effective, large-scale production methods, further expanding the potential of oligonucleotide-based therapies and precision medicine.

Oligonucleotide Synthesis Market Insights

North America is projected to hold the largest share of the oligonucleotide synthesis market in 2024. This leadership is attributed to the region's advanced healthcare infrastructure, significant investments in genomic research, and the strong presence of key industry players. The region is at the forefront of drug development, particularly in antisense and siRNA-based therapies, which are increasingly utilized to treat cancer, genetic disorders, and infectious diseases.

Favorable regulatory policies, including expedited FDA approvals for innovative oligonucleotide treatments, further accelerate market growth. Additionally, government funding and private sector initiatives focused on precision medicine and personalized therapies contribute to the market's expansion. The high prevalence of chronic diseases and a well-established biotechnology industry further reinforce North America's dominance in oligonucleotide synthesis.

According to DelveInsight's findings, Huntington's disease was more common in the geriatric population (≥60 years). In the 7MM, more than 21,000 prevalent cases were observed in people aged more than 60 years. As per DelveInsight's estimates, the total diagnosed prevalent cases of Huntington's disease in the United States was more than 50% of total cases in the 7MM in 2023.

Oligonucleotide-based therapies, such as antisense oligonucleotides (ASOs), are designed to specifically target and reduce the production of the toxic mutant huntingtin protein, a key factor in disease progression. The growing demand for precision medicine for Huntington's disease, alongside advancements in delivery technologies and clinical trials for ASO therapies, has heightened the need for high-quality oligonucleotide synthesis.

Cancer, driven by genetic mutations and abnormal gene expression, represents a major area for oligonucleotide-based interventions. Treatments such as ASOs and siRNAs function by silencing oncogenes or reactivating tumor suppressor genes, addressing the genetic underpinnings of the disease. For complex cancers such as breast, lung, and colorectal cancers, oligonucleotide-based therapies offer a promising strategy to modulate specific molecular pathways involved in tumor growth and resistance to treatment. Consequently, the demand for oligonucleotide synthesis continues to rise across the region.

To know more about why North America is leading the market growth in the oligonucleotide synthesis market, get a snapshot of the Oligonucleotide Synthesis Market Outlook

Oligonucleotide Synthesis Market Dynamics

The oligonucleotide synthesis market is experiencing rapid growth, driven by increasing applications in therapeutics, diagnostics, and research . The demand for custom oligonucleotides has surged due to advancements in gene therapy, antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and mRNA-based therapeutics . Companies are investing heavily in automation and high-throughput synthesis technologies to meet the growing need for precision and scalability. Moreover, the expansion of synthetic biology and CRISPR-based genome editing has further fueled market expansion, as researchers require high-quality oligos for gene modification and functional studies.

One of the key market dynamics is the shift towards more cost-effective and scalable synthesis methods . Traditional solid-phase synthesis techniques are being refined to improve yield and purity while reducing production costs. Additionally, enzymatic synthesis is emerging as a promising alternative, offering potential benefits in terms of sustainability and reduced chemical waste. Leading players in the market, including Thermo Fisher Scientific, Integrated DNA Technologies, and Eurofins Genomics , are continuously enhancing their capabilities to stay ahead in this competitive space.

Regulatory challenges also play a crucial role in shaping the oligonucleotide synthesis market. The increasing use of oligos in therapeutics has prompted stricter quality control measures and compliance requirements from regulatory bodies such as the FDA and EMA . Companies must navigate complex approval pathways for oligonucleotide-based drugs, which can impact time-to-market and development costs . However, advancements in analytical techniques and process optimization are helping to streamline regulatory compliance and improve product consistency.

Partnerships and collaborations are another significant trend influencing market dynamics. Pharmaceutical and biotech companies are increasingly partnering with oligonucleotide manufacturers to secure a reliable supply chain and accelerate drug development. Custom oligo service providers are also expanding their offerings to include design consultation , GMP-grade manufacturing, and bioinformatics support . This trend highlights the growing integration of oligonucleotide synthesis with broader biopharmaceutical and genomic medicine advancements.

Looking ahead, the oligonucleotide synthesis market is expected to continue expanding, driven by innovations in nucleic acid-based therapies and increased investment in personalized medicine. With the rise of novel drug modalities such as aptamers and self-amplifying RNA, the need for high-quality synthetic oligonucleotides will only intensify. Companies that can leverage advanced synthesis technologies, maintain regulatory compliance, and provide flexible, high-throughput solutions will be well-positioned for growth in this dynamic and evolving industry.

Get a sneak peek at the oligonucleotide synthesis market dynamics @ Oligonucleotide Synthesis Market Dynamics Analysis

Report Metrics	Details
Coverage	Global
Study Period	2022–2032
Oligonucleotide Synthesis Market CAGR	~10%
Oligonucleotide Synthesis Market Size by 2032	USD 7.3 Billion
Key Oligonucleotide Synthesis Companies	Thermo Fisher Scientific Inc., Agilent Technologies, Merck KGaA, Bio-Synthesis Inc., Ajinomoto Bio-Pharma Services, CordenPharma, Creative Biolabs, Ella Biotech, Eurofins Genomics, Future synthesis, Integrated DNA Technologies, Kaneka Eurogentec, LGC Biosearch Technologies, Microsynth, Nitto Avecia, Ribo Biotechnology, STA Pharmaceutical, Sumitomo Chemical, TriLink Biotechnologies, Sarepta Therapeutics, among others

Oligonucleotide Synthesis Market Assessment

• Oligonucleotide Synthesis Market Segmentation
  • Oligonucleotide Synthesis Market Segmentation By Product Type: Synthesized Oligonucleotide, Reagents & Consumables, and Equipment
  • Oligonucleotide Synthesis Market Segmentation By Application: Research, Therapeutic, and Diagnostic
  • Oligonucleotide Synthesis Market Segmentation By End-User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Diagnostic Laboratories and CROs & CMOs
  • Oligonucleotide Synthesis Market Segmentation By Geography : North America, Europe, Asia-Pacific, and Rest of World
• Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

Which MedTech key players in the oligonucleotide synthesis market are set to emerge as the trendsetter explore @ Oligonucleotide Synthesis Companies

Table of Contents

1	Oligonucleotide Synthesis Market Report Introduction
2	Oligonucleotide Synthesis Market Executive Summary
3	Competitive Landscape
4	Regulatory Analysis
5	Oligonucleotide Synthesis Market Key Factors Analysis
6	Oligonucleotide Synthesis Market Porter's Five Forces Analysis
7	Oligonucleotide Synthesis Market Layout
8	Oligonucleotide Synthesis Market Company and Product Profiles
9	KOL Views
10	Project Approach
11	About DelveInsight
12	Disclaimer & Contact Us

Interested in knowing the oligonucleotide synthesis market by 2032? Click to get a snapshot of the Oligonucleotide Synthesis Market Trends

Related Reports

Contract Development Manufacturing Organization Market

Contract Development Manufacturing Organization Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CDMO companies, including Patheon (Thermo Fisher Scientific), Catalent,Inc, Laboratoire Elaiapharm, The Lubrizol Corporation, Cambrex Corporation, Recipharm (EQT), Merck & Co., Inc, AGC Biologics, Nerpharma S.r.l, Pfizer CenterOne (Pfizer Inc), EMERGENT, Onyx Scientific Limited, Lonza, Siegfried Holding AG, CordenPharma International, FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Delpharm, Center for Breakthrough Medicines, and WuXi Biologics , among others.

RNA Interference Pipeline

RNA Interference Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key RNA interference companies, including Silence Therapeutics, Janssen Research & Development, Eli Lilly and Company, Arrowhead Pharmaceuticals, Sylentis, Sirnaomics, Dicerna Pharmaceuticals, Suzhou Ribo Life Science, Alnylam Pharmaceuticals, Suzhou Ribo Life Science, Vir Biotechnology, Arbutus Biopharma, Silenseed, OliX Pharmaceuticals, Bio-Path Holdings, among others.

Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market

Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key global messenger RNA -based vaccines and therapeutics companies, including Moderna, Inc., BioNTech SE, CureVac N.V., Arcturus Therapeutics, Translate Bio, Inc., GSK, among others.

Global Messenger RNA Market

Global Messenger RNA Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key global mRNA companies, including Translate Bio, AstraZeneca, Moderna, Roche (Genentech), BioNTech, Sanofi, Moderna, CureVac, Arcturus, among others.

mRNA Vaccines And Therapeutics Market

mRNA Vaccines And Therapeutics Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key mRNA vaccines and therapeutics companies, including Pfizer Inc., BioNTech SE, Moderna, Inc., Gennova Biopharmaceuticals Limited, GSK plc., Daiichi Sankyo, Arcturus, Boehringer Ingelheim International GmbH, Ethris GmbH, CureVac SE, AIM Vaccine Corporation, Charoen Pokphand Group, Argos Therapeutics Inc., Sanofi, Kernal Biologics Inc, among others.

DelveInsight's Pharma Competitive Intelligence Service : Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.

Other Business Consulting Services

Healthcare Conference Coverage

Pipeline Assessment

Healthcare Licensing Services

Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

CONTACT: Contact Us Shruti Thakur ... +14699457679

MENAFN25022025004107003653ID1109248247